Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2008
- Admin. routes
- parenteral
- Indications
- rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis
via ChEMBL · EBI
Research
1,417 papers- Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
- Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial.Annals of the rheumatic diseases · 2025
- Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.Skin therapy letter · 2021
- Certolizumab pegol.mAbs · 2010
- Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.Annals of the rheumatic diseases · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 5 more facts
- defined daily dose
- 14
- medical condition treated
- ankylosing spondylitis
- Commons category
- Certolizumab pegol
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0